Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model

Immunology Letters

Volumn 148, Issue 2, 2012, Pages 117-125

  Daemi, Amin ^a,b   Bolhassani, Azam ^a   Rafati, Sima ^a   Zahedifard, Farnaz ^a   Hosseinzadeh, Sahar ^a   Doustdari, Fatemeh ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cervical cancer; DNA vaccine; Electroporation; Gp96; Heat shock protein; Human papillomavirus

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HUMAN PAPILLOMAVIRUS 16 E7 DNA VACCINE; HUMAN PAPILLOMAVIRUS 16 E7 GLYCOPROTEIN 96 C TERMINAL FUSION PROTEIN DNA VACCINE; HUMAN PAPILLOMAVIRUS 16 E7 GLYCOPROTEIN 96 N TERMINAL FUSION PROTEIN DNA VACCINE; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; ELECTROPORATION; FEMALE; HUMORAL IMMUNITY; IMMUNOPROPHYLAXIS; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SURVIVAL RATE; TUMOR REGRESSION; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; DNA, VIRAL; ELECTROPORATION; FEMALE; GLYCOPROTEINS; GREEN FLUORESCENT PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION; VACCINES, DNA;

EID: 84869841753     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.10.003     Document Type: Article

References (63)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2:342-350.
2. Gatta G., Lasota M.B., Verdecchia A. Survival of European women with gynaecological tumors during the period 1978-1989. Eur J Cancer 1998, 34:2218-2225.
3. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995, 87:796-802.
4. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004, 4:46-54.
5. Donnelly J.J., Wahren B., Liu M.A. DNA vaccines: progress and challenges. J Immunol 2005, 175:633-639.
6. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164:4635-4640.
7. Lin K., Roosinovich E., Ma B., Hung C.F., Wu T.C. Therapeutic HPV DNA vaccines. Immunol Res 2010, 1-23.
8. Babiuk S., Baca-Estrada M.E., Foldvari M., Storms M., Rabussay D., Widera G. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002, 20:3399-3408.
9. Luxembourg A., Evans C.F., Hannaman D. Electroporation-based DNA immunization: translation to the clinic. Expert Opin Biol Ther 2007, 7:1647-1664.
10. Binder R.J. Heat shock protein-based vaccines for cancer and infectious disease. Expert Rev Vaccine 2008, 7:383-393.
11. Javid B., MacAry P.A., Lehner P.J. Structure and function: heat shock proteins and adaptive immunity. J Immunol 2007, 179:2035-2040.
12. Kim L.S., Kim J.H. Heat shock protein as molecular targets for breast cancer therapeutics. J Breast C 2011, 14:167-174.
13. Nicchitta C.V. Re-evaluating the role of heat shock protein-peptide interactions in tumor immunity. Nat Rev Immunol 2003, 3:427-432.
14. Rapp U.K., Kaufmann S.H. DNA vaccination with Gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol 2004, 16:597-605.
15. Yan J., Liu X., Wang Y., Jiang X., Liu H., Wang M., et al. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of Gp96. J Gene Med 2007, 9:107-121.
16. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002, 2:185-194.
17. Doody A.D., Kovalchin J.T., Mihalyo M.A., Hagymasi A.T., Drake C.G., Adler A.J. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol 2004, 172:6087-6092.
18. Robert J., Ramanayake T., Maniero G.D., Morales H., Chida A.S. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J Immunol 2008, 180:3176-3182.
19. Biswas C., Sriram U., Ciric B., Ostrovsky O., Gallucci S., Argon Y. The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells. Int Immunol 2006, 18:1147-1157.
20. Bolhassani A., Zahedifard F., Taghikhani M., Rafati S. Enhanced immunogenicity of HPV16 E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 2008, 26:3362-3370.
21. Ji H., Chang E.Y., Lin K.Y., Kurman R.J., Pardoll D.M., Wu T.C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998, 78:41-45.
22. Li Y., Subjeck J., Yang G., Repasky E., Wang X.Y. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 2006, 24:5360-5370.
23. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22:2489-2493.
24. Seo S.H., Jin H.T., Park S.H., Youn J.I., Sung Y.C. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic anti-tumor effect by antigen engineering and electroporation. Vaccine 2009, 27:5906-5912.
25. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000, 60:1035-1042.
26. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995, 269:1585-1588.
27. Wanga S., Qiua L., Liub G., Li Y., Zhanga X., Jin W., et al. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice. Vaccine 2011, 29:6342-6351.
28. Pakravan N., Soleimanjahi H., Hassan Z.M. Gp96 C-terminal improves Her2/neu DNA vaccine. J Gene Med 2010, 12:345-353.
29. Li H.T., Yan J.B., Li J., Zhou M.H., Zhu X.D., Zhang Y.X., et al. Enhancement of humoral immune responses to HBsAg by heat shock protein Gp96 and its N-terminal fragment in mice. World J Gastroenterol 2005, 11:2858-2863.
30. Li H., Zhou M., Han J., Zhu X., Dog T., Gao C.F., et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 2005, 174:195-204.
31. Pakravan N., Hashemi S.M., Hassan Z.M. Adjuvant activity of Gp96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent. Cell Stress Chaperones 2011, 16:41-48.
32. Wang S., Zhang C., Zhang L., Li J., Huang Z., Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008, 26:2100-2110.
33. Rosati M., Valentin A., Jalah R., Patel V., Gegerfelt A., Bergamaschi C., et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008, 26:5223-5229.
34. Ahlen G., Soderholm J., Tjelle T., Kjeken R., Frelin L., Hoglund U., et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus non-structural 3/4A DNA by increased local DNA uptake, protein expression, inflammation and infiltration of CD3+ T cells. J Immunol 2007, 179:4741-4753.
35. LeBlanc R., Vasquez Y., Hannaman D., Kumar N. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 2008, 26:185-192.
36. Luxembourg A., Hannaman D., Nolan E., Ellefsen B., Nakamura G., Chau L., et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 2008, 26:5216-5222.
37. Smorlesi A., Papalini F., Amici A., Orlando F., Pierpaoli S., Mancini C., et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 2006, 24:1766-1775.
38. Cipriani B., Fridman A., Bendtsen C., Dharmapuri S., Mennuni C., Pak I., et al. Therapeutic vaccination halts disease progression in BALB-neu T mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther 2008, 19:670-680.
39. Roos A.K., Moreno S., Leder C., Pavlenko M., King A., Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006, 13:320-327.
40. Lucas M.L., Heller L., Coppola D., Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16, F10 melanoma. Mol Ther 2002, 5:668-675.
41. Ahmad S., Casey G., Sweeney P., Tangney M., O'Sullivan G.C. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 2009, 17:1101-1108.
42. Ahmad S., Casey G., Sweeney P., Tangney M., O'Sullivan G.C. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther 2010, 8:1-13.
43. Best S.R., Peng S., Juang C.M., Hung C.F., Hannaman D., Saunders J.R., et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27:5450-5459.
44. Manjili M.H., Wang X.Y., Chen X., Martin T., Repasky E.A., Henderson R., et al. HSP110-Her2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in Her2/neu transgenic mice. J Immunol 2003, 171:4054-4061.
45. He Y.F., Wang X.H., Zhang G.M., Chen H.T., Zhang H., Feng Z.H. Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 2005, 54:891-897.
46. Kmieciak M., Knutson K.L., Dumur C.I., Manjili M.H. Her2/neu antigen loss and relapse of mammary carcinoma are activity induced by T cell mediated anti-tumor immune responses. Eur J Immunol 2007, 37:675-685.
47. Liu Z., Li X., Qiu L., Zhang X., Chen L., Cao S., et al. Treg suppress CTL responses upon immunization with HSP gp96. Eur J Immunol 2009, 39:3110-3120.
48. Titomirov A., Sukharev S., Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1991, 1088:131.
49. Nomura M., Nakata Y., Inoue T., Uzawa A., Itamura S., Nerome K., et al. In vivo induction of cytotoxic T lymphocytes specific for a single epitope introduced into an un-related molecule. J Immunol Methods 1996, 193:41.
50. Heller R., Jaroszeski M., Atkin A., Moradpour D., Gilbert R., Wands J., et al. In vivo gene electro-injection and expression in rat liver. FEBS Lett 1996, 389:225.
51. Suzuki T., Shin B.C., Fujikura K., Matsuzaki T., Takata K. Direct gene transfer into rat liver cells by in vivo electroporation. FEBS Lett 1998, 425:436.
52. Nishi T., Yoshizato K., Yamashiro S., Takeshima H., Sato K., Hamada K., et al. High efficiency in vivo gene transfer using intra-arterial plasmid DNA injection following in vivo electroporation. Cancer Res 1996, 56:1050.
53. Nishi T., Dev S., Yoshizato K., Kuratsu J., Ushio Y. Treatment of cancer using pulsed electric field in combination with chemotherapeutic agents or genes. Hum Cell 1996, 10:81.
54. Rols M.P., Delteil C., Golzio M., Dumond P., Cros S., Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998, 16:168.
55. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998, 16:867.
56. Brave A., Nystrom S., Roos A.K., Applequist S.E. Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses. Immunol Cell Biol 2011, 89:492-496.
57. Chu N.R., Wu H.B., Wu T.C., Boux L.J., Siegel M.I., Mizzen L.A. Immunotherapy of a HPV type 16 E7-expressing tumor by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guerin (BCG) HSP65 and HPV16 E7. Clin Exp Immunol 2000, 121:216-225.
58. Zhou Y., Fang F., Chen J., Wang H., Chang H., Yang Z., et al. Electroporation at low voltages enables DNA vaccine to provide protection against a lethal H5N1 Avian Influenza virus challenge in mice. Intervirology 2008, 51:241-246.
59. Vandermeulena G., Richiardi H., Escrioub V., Nic J., Fournierc P., Schirrmacherc V., et al. Skin-specific promoters for genetic immunization by DNA electroporation. Vaccine 2009, 27:4272-4277.
60. Lee H., Park J.B., Cheong M., Seok Choi Y., Park D., Sin J.I. Anti-tumor therapeutic and anti-metastatic activity of electroporation-delivered HPV16 E7 DNA Vaccines: a possible mechanism for enhanced tumor control. DNA Cell Biol 2011, 30:975-985.
61. Pakravan N., Hassan Z.M. Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model. Cell Stress Chaperones 2011, 16:449-457.
62. Pakravan N., Soudi S., Hassan Z.M. N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine. Cell Stress Chaperones 2010, 15:631-638.
63. Pakravan N., Langroudi L., Hajimoradi M., Hassan Z.M. Co-administration of gp96 and Her2/neu DNA vaccine in a Her2 breast cancer model. Cell Stress Chaperones 2010, 15:977-984.